Frontiers in Endocrinology (May 2024)

Atosiban interacts with growth hormones as adjuvants in frozen-thawed embryo transfer cycles

  • Haixiao Chen,
  • Jiali Cai,
  • Jiali Cai,
  • Xiaohua Sun,
  • Lanlan Liu,
  • Lanlan Liu,
  • Zhenfang Liu,
  • Peng Gao,
  • Peng Gao,
  • Xiaoming Jiang,
  • Xiaoming Jiang,
  • Jianzhi Ren,
  • Jianzhi Ren

DOI
https://doi.org/10.3389/fendo.2024.1380778
Journal volume & issue
Vol. 15

Abstract

Read online

ObjectiveTo investigate the interaction between atosiban and growth hormone (GH) as adjuvants in frozen-thawed embryo transfer (FET) cyclesMethodA total of 11627 patients who underwent FET at Xiamen University Affiliated Chenggong Hospital between January 2018 to December 2022 were retrospectively analyzed. Among them, 482 patients received atosiban and 275 patients received GH. The interactions were estimated by comparing the odds ratio (OR) for pregnancy comparing patients with or without atosiban adjuvant in cohorts stratified according to the presence of GH use in either the overall cohort or a propensity score (PS) matched cohort. An interaction term (atosiban × GH) was introduced to a multivariate model to calculate the ratio of OR (ORR) adjusted for confounders.ResultsFor all patients receiving atosiban administration, no obvious effect on pregnancy was observed in comparison with either matched or unmatched controls. However, when the patients were stratified according to GH administration, atosiban showed a significant association with clinical pregnancy in comparison with either matched or unmatched controls among patients with GH treatment with rate ratios (RR) of 1.32 (95%CI: 1.05,1.67) and 1.35 (95%CI: 1,1.82), respectively. On the other hand, however, the association was absent among patients without GH treatment. The adjusted ORRs in both matched and unmatched cohorts were 2.44 (95%CI: 1.07,5.84) and 1.95 (95%CI: 1.05, 3.49) respectively.ConclusionThe combination use of atosiban and GH in FET cycles is potentially beneficial to the pregnancy. However, indications for the use of atosiban and GH may need further assessment.

Keywords